Prime Highlights
- Amazon Bio Discovery aims to speed up drug research using AI and lab integration.
- The platform allows scientists to design, test, and refine drug candidates in a single system.
Key Facts
- Amazon Web Services is a global cloud computing provider serving major industries, including healthcare.
- The platform connects AI-based drug design with physical lab testing through integrated partners.
Background
Amazon Web Services (AWS) introduced Amazon Bio Discovery as a new AI technology that helps speed up the initial stages of drug research. The product enables researchers to develop new drugs through its specific focus on antibody research.
This technology provides scientists with unique biological AI models based on extensive scientific data sets. These models can generate and assess potential drug molecules, reducing the time needed in the initial discovery phase. Furthermore, the system has an AI assistant that helps scientists in selecting appropriate models, modifying inputs, and testing outputs through language rather than code.
The linking of technology development and technology assessment is, possibly, one of its main features. Scientists can send candidates to cooperating labs for synthesis and testing. The obtained results are then fed back into the system, and the process of continually improving the design can be achieved.
Scientists can also take advantage of being able to use their own data from experiments when creating AI models using this software. This makes the process more accurate when making predictions, without having to be technically savvy or needing expensive equipment. The entire data system used is kept confidential and protected.
Initial partnerships have been fruitful, and scientists can now develop and test high quantities of antibody candidates in weeks rather than months. The company reckons that this can go a long way in streamlining the time required to bring new therapies closer to the development stage.
